Castilla EE et al. Thalidomide, a current teratogen in South America. Teratology, 1996, 54: 273-277.
Lazarou J et al. Incidence of ADR in hospitalized patients: a meta analysis of prospective studies. Journal of the American Medical Association, 1998, 279:1000-1005.
Linquist AM. Seeing and observing in international pharmacovigilance. Uppsala, World Health Organization Collaborating Centre for International Drug Monitoring, 2003.
Pannikar V. The return of thalidomide: new uses and renewed concerns. WHO Pharmaceuticals Newsletter, 2003, 2:11.
WHO. Safety monitoring of medicinal products. In: Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. Geneva, World Health Organization, 1995: Annex 3 (WHO Technical Report Series, No. 850).
WHO. Effective communications in pharmacovigilance: the Erice Report. Uppsala, World Health Organization Collaborating Centre for International Drug Monitoring, 1998.
WHO. Safety monitoring of medicines. Guidelines for setting up and running a pharmacovigilance centre. Geneva, World Health Organization, 2000.
WHO. Aide Memoire for a national strategy for safe drugs and their appropriate use. Essential Medicines and Medicines Policy. Geneva, World Health Organization, 2001 (http://www.who.int/medicines/library/qsm/aidememdrugsafety.pdf; accessed 15 October 2004).
WHO. Safety of medicines. A guide to detecting and reporting adverse drug reactions. Geneva, World Health Organization, 2002 (WHO/EDM/QSM/2002.2).
WHO. Safety monitoring of medicinal products. The importance of pharmacovigilance. Geneva, World Health Organization, 2002.
WHO. WHO international drug monitoring: cerivastatin and gemfibrozil. WHO Drug Information, 2002, 16:8.
WHO. Expecting the worst. Anticipating, preventing and managing medicinal product crises. Uppsala, World Health Organization Collaborating Centre for International Drug Monitoring, 2002.
WHO. Dialogue in pharmacovigilance - more effective communication. Uppsala, World Health Organization Collaborating Centre for International Drug Monitoring, 2002.
WHO. The World Health Organization Collaborating Centre for International Drug Monitoring [web site]. The World Health Organization Collaborating Centre for International Drug Monitoring, Uppsala (http://www.who-umc.org, accessed 15 October 2004).
van Boxtel CJ, Santoso B, Edwards IR (Eds).Drug benefits and risks: International textbook of clinical pharma-cology. John Wiley & Sons, Chichester, 2001.
Contacts in WHO Regional Offices:
Regional Office for Africa:
Dr Jean-Marie Trapsida
Coordinator, Essential Drugs and Medicines Policy
Tel: +242 8 39258 E-mail: email@example.com
Regional Office for the Americas:
Dr Rosario D'Alessio
Regional Adviser for Pharmaceuticals
Tel: +1 202 974 3282 E-mail: firstname.lastname@example.org
Regional Office for the Eastern Mediterranean:
Mr Mohamed Bin Shahna
Acting Regional Adviser, Pharmaceuticals
Tel: +20 2 276 5301 E-mail: email@example.com
Regional Office for Europe:
Mr Kees de Joncheere
Tel: +45 3 917 14 32 E-mail: firstname.lastname@example.org
Regional Office for South-East Asia:
Dr Krisantha Weerasuriya
Regional Adviser, Essential Drugs and Medicines Policy
Tel: +91 11 2337 0804 (ext 26314)
Regional Office for the Western Pacific:
Dr Budiono Santoso
Tel: +63 2 528 9846 E-mail: email@example.com
Contacts at WHO Headquarters:
Essential Drugs and Medicines Policy
Health Technology and Pharmaceuticals Cluster
WHO Headquarters, Geneva, Switzerland:
Dr Hans Hogerzeil
Director a.i., Essential Drugs and Medicines Policy
Tel: +41 22 791 4443 E-mail: firstname.lastname@example.org
Team Coordinator, Policy, Access and Rational Use
Tel: +41 22 791 3528 E-mail: email@example.com
Dr Lembit Rägo
Team Coordinator, Quality and Safety: Medicines
Tel: +41 22 791 4420 E-mail: firstname.lastname@example.org
Dr Germán Velásquez
Team Coordinator, Drug Action Programme
Tel: +41 22 791 3509 E-mail: email@example.com
Dr Xiaorui Zhang
Team Coordinator, Traditional Medicine
Tel: +41 22 791 3639 E-mail: firstname.lastname@example.org
© World Health Organization 2004.
All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: email@example.com).
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.